The response rate of non-M3 acute myeloid leukemia (AML) to all trans retinoic acid has been limited. Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA. We therefore performed a phase I study of combination bexarotene and decitabine in elderly and relapsed AML patients. We found that this combination was well tolerated, although outcomes were modest (1 CRi, and 3 PR among 19 patients). Correlative studies found that patients with clinical response had increased differentiation to bexarotene both in vivo and ex vivo, suggesting that pre-treatment analysis might identify a more susceptible subgroup of patients. Am. J. Hematol. 89:E103-E108, 2014.

Original languageEnglish
Pages (from-to)E103-E108
JournalAmerican journal of hematology
Issue number8
StatePublished - Aug 2014


Dive into the research topics of 'A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML'. Together they form a unique fingerprint.

Cite this